Cargando…
Bronchodilator Responsiveness Defined by the 2005 and 2021 ERS/ATS Criteria in Patients with Asthma as Well as Chronic Obstructive Pulmonary Disease
BACKGROUND: In the 2021 ERS/ATS interpretive strategies for routine lung function tests, a positive bronchodilator response (BDR) was updated as a change of >10% relative to the predicted value in forced expiratory volume in 1 second (FEV(1)) or forced vital capacity (FVC). We aimed to explore th...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9586173/ https://www.ncbi.nlm.nih.gov/pubmed/36274994 http://dx.doi.org/10.2147/COPD.S385733 |
_version_ | 1784813639916584960 |
---|---|
author | Li, Yun Lin, Junfeng Wang, Zihui Wang, Zhufeng Tan, Lunfang Liu, Shuyi Huang, Jinhai Gao, Yi Zheng, Jinping |
author_facet | Li, Yun Lin, Junfeng Wang, Zihui Wang, Zhufeng Tan, Lunfang Liu, Shuyi Huang, Jinhai Gao, Yi Zheng, Jinping |
author_sort | Li, Yun |
collection | PubMed |
description | BACKGROUND: In the 2021 ERS/ATS interpretive strategies for routine lung function tests, a positive bronchodilator response (BDR) was updated as a change of >10% relative to the predicted value in forced expiratory volume in 1 second (FEV(1)) or forced vital capacity (FVC). We aimed to explore the differences between the 2005 and 2021 ERS/ATS criteria applied to patients with asthma as well as chronic obstructive pulmonary disease (COPD). METHODS: BDR test data about asthma patients aged 6–80 years and COPD patients aged 18–80 years were derived from the National Respiratory Medicine Center, First Affiliated Hospital of Guangzhou Medical University, from January 2017 to March 2022. BDR results defined by the 2005 and 2021 ERS/ATS criteria were named 2005-BDR and 2021-BDR, respectively. We compared differences between 2005-BDR and 2021-BDR and analyzed the trend in the proportion of positive BDR (BDR+) with the level of airflow obstruction. RESULTS: A total of 4457 patients with asthma and 7764 patients with COPD were included in the analysis. The percentages of 2005-BDR+ and 2021-BDR+ were 63.32% and 52.84% for asthma, 30.92% and 22.94% for COPD, respectively. Of patients with 2005-BDR+, 81.86% for asthma and 70.18% for COPD showed 2021-BDR+ results, and these patients had higher FEV(1)%pred, FVC%pred (all P<0.05). Whichever BDR criterion was adopted, the proportion of BDR+ had an upward linear trend with the increased degree of airflow obstruction in COPD, but exhibited an approximate inverted U-shaped curve in asthma. In COPD, the proportion of BDR(FEV1) was negatively associated with the degree of airflow obstruction, while BDR(FVC) was positively associated (all P<0.05). CONCLUSION: Compared with 2005-BDR+, the proportion of 2021-BDR+ reduced markedly in patients with asthma and COPD, but their trends with the degree of airflow obstruction did not change. Patients with consistent BDR+ had higher initial FEV(1)%pred and FVC%pred. |
format | Online Article Text |
id | pubmed-9586173 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-95861732022-10-22 Bronchodilator Responsiveness Defined by the 2005 and 2021 ERS/ATS Criteria in Patients with Asthma as Well as Chronic Obstructive Pulmonary Disease Li, Yun Lin, Junfeng Wang, Zihui Wang, Zhufeng Tan, Lunfang Liu, Shuyi Huang, Jinhai Gao, Yi Zheng, Jinping Int J Chron Obstruct Pulmon Dis Original Research BACKGROUND: In the 2021 ERS/ATS interpretive strategies for routine lung function tests, a positive bronchodilator response (BDR) was updated as a change of >10% relative to the predicted value in forced expiratory volume in 1 second (FEV(1)) or forced vital capacity (FVC). We aimed to explore the differences between the 2005 and 2021 ERS/ATS criteria applied to patients with asthma as well as chronic obstructive pulmonary disease (COPD). METHODS: BDR test data about asthma patients aged 6–80 years and COPD patients aged 18–80 years were derived from the National Respiratory Medicine Center, First Affiliated Hospital of Guangzhou Medical University, from January 2017 to March 2022. BDR results defined by the 2005 and 2021 ERS/ATS criteria were named 2005-BDR and 2021-BDR, respectively. We compared differences between 2005-BDR and 2021-BDR and analyzed the trend in the proportion of positive BDR (BDR+) with the level of airflow obstruction. RESULTS: A total of 4457 patients with asthma and 7764 patients with COPD were included in the analysis. The percentages of 2005-BDR+ and 2021-BDR+ were 63.32% and 52.84% for asthma, 30.92% and 22.94% for COPD, respectively. Of patients with 2005-BDR+, 81.86% for asthma and 70.18% for COPD showed 2021-BDR+ results, and these patients had higher FEV(1)%pred, FVC%pred (all P<0.05). Whichever BDR criterion was adopted, the proportion of BDR+ had an upward linear trend with the increased degree of airflow obstruction in COPD, but exhibited an approximate inverted U-shaped curve in asthma. In COPD, the proportion of BDR(FEV1) was negatively associated with the degree of airflow obstruction, while BDR(FVC) was positively associated (all P<0.05). CONCLUSION: Compared with 2005-BDR+, the proportion of 2021-BDR+ reduced markedly in patients with asthma and COPD, but their trends with the degree of airflow obstruction did not change. Patients with consistent BDR+ had higher initial FEV(1)%pred and FVC%pred. Dove 2022-10-17 /pmc/articles/PMC9586173/ /pubmed/36274994 http://dx.doi.org/10.2147/COPD.S385733 Text en © 2022 Li et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Li, Yun Lin, Junfeng Wang, Zihui Wang, Zhufeng Tan, Lunfang Liu, Shuyi Huang, Jinhai Gao, Yi Zheng, Jinping Bronchodilator Responsiveness Defined by the 2005 and 2021 ERS/ATS Criteria in Patients with Asthma as Well as Chronic Obstructive Pulmonary Disease |
title | Bronchodilator Responsiveness Defined by the 2005 and 2021 ERS/ATS Criteria in Patients with Asthma as Well as Chronic Obstructive Pulmonary Disease |
title_full | Bronchodilator Responsiveness Defined by the 2005 and 2021 ERS/ATS Criteria in Patients with Asthma as Well as Chronic Obstructive Pulmonary Disease |
title_fullStr | Bronchodilator Responsiveness Defined by the 2005 and 2021 ERS/ATS Criteria in Patients with Asthma as Well as Chronic Obstructive Pulmonary Disease |
title_full_unstemmed | Bronchodilator Responsiveness Defined by the 2005 and 2021 ERS/ATS Criteria in Patients with Asthma as Well as Chronic Obstructive Pulmonary Disease |
title_short | Bronchodilator Responsiveness Defined by the 2005 and 2021 ERS/ATS Criteria in Patients with Asthma as Well as Chronic Obstructive Pulmonary Disease |
title_sort | bronchodilator responsiveness defined by the 2005 and 2021 ers/ats criteria in patients with asthma as well as chronic obstructive pulmonary disease |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9586173/ https://www.ncbi.nlm.nih.gov/pubmed/36274994 http://dx.doi.org/10.2147/COPD.S385733 |
work_keys_str_mv | AT liyun bronchodilatorresponsivenessdefinedbythe2005and2021ersatscriteriainpatientswithasthmaaswellaschronicobstructivepulmonarydisease AT linjunfeng bronchodilatorresponsivenessdefinedbythe2005and2021ersatscriteriainpatientswithasthmaaswellaschronicobstructivepulmonarydisease AT wangzihui bronchodilatorresponsivenessdefinedbythe2005and2021ersatscriteriainpatientswithasthmaaswellaschronicobstructivepulmonarydisease AT wangzhufeng bronchodilatorresponsivenessdefinedbythe2005and2021ersatscriteriainpatientswithasthmaaswellaschronicobstructivepulmonarydisease AT tanlunfang bronchodilatorresponsivenessdefinedbythe2005and2021ersatscriteriainpatientswithasthmaaswellaschronicobstructivepulmonarydisease AT liushuyi bronchodilatorresponsivenessdefinedbythe2005and2021ersatscriteriainpatientswithasthmaaswellaschronicobstructivepulmonarydisease AT huangjinhai bronchodilatorresponsivenessdefinedbythe2005and2021ersatscriteriainpatientswithasthmaaswellaschronicobstructivepulmonarydisease AT gaoyi bronchodilatorresponsivenessdefinedbythe2005and2021ersatscriteriainpatientswithasthmaaswellaschronicobstructivepulmonarydisease AT zhengjinping bronchodilatorresponsivenessdefinedbythe2005and2021ersatscriteriainpatientswithasthmaaswellaschronicobstructivepulmonarydisease |